Recent clinical trials showed that hepatic steatosis was improved in patients with NAFLD after treatment with low-dose levothyroxine or TRβ-selective agonist, resmetirom (MGL-3196) [50]. The gene discussed is THRB; the disease is Hepatic steatosis.